News

Issue of Equity
Issue of Equity
September 1, 2017

Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”)  as payment for professional services.

Directorate Changes
Directorate Changes
August 1, 2017

Proteome Sciences (AIM:PRM), is pleased to announce the appointment of Dr Ursula Ney as a Non-executive Director of the Company, with immediate effect, replacing Professor William Dawson who is standing down after providing 20 years of valuable service to the Company.

Interim results for the six months ended 30 June 2017
Interim results for the six months ended 30 June 2017
July 25, 2017

Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:

“We are pleased to report that performance during the first six months of 2017 has been broadly in line with expectations, and revenues significantly ahead of the equivalent period in 2016 driven by strong growth in TMT® sales. This was achieved despite predictable disruption resulting from the consolidation of our laboratory capabilities in Frankfurt and the relocation of our head office to London; these activities increased our administrative expenses for the period compared with 2016 but are expected to generate cost savings from the second half of 2017 onwards....."

Notice of Results
Notice of Results
July 11, 2017

Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.

Stroke Diagnostic Presentation at EuroMedLab 2017 – Research Milestone Achieved
Stroke Diagnostic Presentation at EuroMedLab 2017 – Research Milestone Achieved
June 30, 2017

We are pleased to announce that Randox Laboratories Ltd, (“Randox”) presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.

New Registered Address
New Registered Address
June 12, 2017

 Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London.

Director/PDMR Shareholding
Director/PDMR Shareholding
May 15, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 10 May 2017 it purchased 97,314 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,443,715 equivalent to 18.48% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
May 10, 2017

Following the Purchases Vulpes has a total direct and indirect interest in 54,346,401 equivalent to 18.44% of Proteome Sciences' total issued share capital. The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has made the following purchases of ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") (the “Purchases”):

Director/PDMR Shareholding
Director/PDMR Shareholding
May 5, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 1,329 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 4.9p per Ordinary Share (the “First Purchase”). The Company has also received notification that on 03 May 2017 Vulpes purchased a further 240 Ordinary Shares at a price of 4.85p per Ordinary Share (the “Second Purchase”) (together with the First Purchase, “the Purchases”). Following the Purchases Vulpes has a total direct and indirect interest in 54,145,284 equivalent to 18.38% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
May 5, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.37% of Proteome Sciences' total issued share capital.